Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue

Yuan, Shengtao; Li, Kai-Zong; Wang, Ling; Dou, Kefeng; Yan, Zhen; Han, Wei; Zhang, Yingqi

doi:10.3748/wjg.v11.i30.4661

Cited by 54 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumors with high levels of expression, either massforming or periductal-infiltrating, have a poorer prognosis than intraductal-papillary tumors that display a lower level of MUC1 expression. In another surgical series, metastases 3 years after surgical resection were higher in the MUC1 positive group of patients with intrahepatic cholangiocarcinoma (43).…”

Section: Inflammation and Carcinogenesismentioning

confidence: 99%

Cholangiocarcinoma: Modern advances in understanding a deadly old disease

Malhi

Gores

2006

Journal of Hepatology

243

193

View full text Add to dashboard Cite

Cholangiocarcinomas are tumors that arise anywhere in the biliary tract, presumably of cholangiocyte origin. The global incidence of this rare disease is on the rise. Several known risk factors exist, and link chronic biliary inflammation to the pathogenesis of cholangiocarcinoma. Among these, amplification of the epidermal growth factor receptor, the interleukin-6 signaling pathway, inducible nitric oxide, erb-2, and cyclooxygenase-2 are well defined. Most patients present late, with a median survival of months. Although, imaging studies and clinical context often indicate cholangiocarcinoma, pathologic and cytologic diagnosis is difficult to obtain. Advanced cytologic tests with fluorescent in situ hybridization or digital image analysis can increase diagnostic sensitivity. Surgical resection is the current therapy of choice for both intrahepatic and ductal cholangiocarcinomas. However, the 5 year survival is poor, with 60 to greater than 90% recurrence rates. In a single center experience, liver transplantation with neoadjuvant chemoirradiation, for highly selected patients has a 5 year disease free survival of greater than 80%. Future targeted therapies will depend on a better understanding of the cellular and molecular biology of cholangiocarcinomas.

show abstract

Section: Inflammation and Carcinogenesismentioning

confidence: 99%

Cholangiocarcinoma: Modern advances in understanding a deadly old disease

Malhi

Gores

2006

Journal of Hepatology

243

193

View full text Add to dashboard Cite

show abstract

“…Of the nine studies that have examined the prognostic value of MUC1 in CC, all except one have demonstrated a significant correlation between MUC1 expression and decreased survival, both on univariate and multivariate survival analyses (61,62,(101)(102)(103)(104)(105)(106)(107).…”

Section: Muc1mentioning

confidence: 99%

Prognostic molecular markers in cholangiocarcinoma: A systematic review

Briggs

Neal

Mann

et al. 2009

European Journal of Cancer

View full text Add to dashboard Cite

The worldwide incidence of cholangiocarcinoma (CC) is steadily rising, the United Kingdom incidence now exceeding 1000 cases per year. It is an aggresive malignancy typified by unresponsiveness to existing chemotherapy and radiotherapy regimes in the vast majority of cases. Surgery offers the only hope of a cure, though postoperative disease recurrence is common, with 5-year survival rates following resection of less then 25%. Developments in molecular techniques and improved understanding of the basis of carcinogenesis in CC has led to examination of the role of biomarkers in predicting poor outcome. This systematic review examines published evidence relating to the prognostic significance of these molecular markers in CC. Of the molecular markers which have been investigated to date p53 mutation, cyclins, proliferation indices, mucins, CA19-9, CRP, and aneuploidy appear to hold significant potential as predictors of outcome in CC. These and other biomarkers may themselves represent novel therapeutic targets for CC.

show abstract

“…However, the incidence is higher in other regions of the world with an overall world incidence of 14.2 per 100,000 population in males and 6.0 per 100,000 population in females and a highest incidence of 53.1 and 34.2, respectively, in Mongolia [2]. Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two main types of primary liver cancer, HCC being more common than cholangiocarcinoma [3,4].…”

mentioning

confidence: 99%